Murray Krahn

21.7k total citations · 2 hit papers
400 papers, 15.9k citations indexed

About

Murray Krahn is a scholar working on Economics and Econometrics, Epidemiology and Hepatology. According to data from OpenAlex, Murray Krahn has authored 400 papers receiving a total of 15.9k indexed citations (citations by other indexed papers that have themselves been cited), including 171 papers in Economics and Econometrics, 86 papers in Epidemiology and 74 papers in Hepatology. Recurrent topics in Murray Krahn's work include Health Systems, Economic Evaluations, Quality of Life (160 papers), Hepatitis C virus research (58 papers) and Liver Disease Diagnosis and Treatment (46 papers). Murray Krahn is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (160 papers), Hepatitis C virus research (58 papers) and Liver Disease Diagnosis and Treatment (46 papers). Murray Krahn collaborates with scholars based in Canada, United States and United Kingdom. Murray Krahn's co-authors include Gary Naglie, George Tomlinson, Allan S. Detsky, Hla‐Hla Thein, Qilong Yi, Gregory J. Dore, Shabbir M.H. Alibhai, Louise B. Russell, David Naimark and Karen E. Bremner and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Murray Krahn

384 papers receiving 15.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

2016 2.2k citations Murray Krahn et al. profile →
Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection

2008 635 citations Hla‐Hla Thein, Qilong Yi et al. profile →

Peers

Countries citing papers authored by Murray Krahn

Since Specialization

Citations

This map shows the geographic impact of Murray Krahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Murray Krahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Murray Krahn more than expected).

Fields of papers citing papers by Murray Krahn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Murray Krahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Murray Krahn. The network helps show where Murray Krahn may publish in the future.

Co-authorship network of co-authors of Murray Krahn

This figure shows the co-authorship network connecting the top 25 collaborators of Murray Krahn. A scholar is included among the top collaborators of Murray Krahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Murray Krahn. Murray Krahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Understanding the Growing Burden of Malignant Pleural Effusion – Epidemiology, Healthcare Utilization, and Cost: A Canadian Perspective 2025 ·Respiration ·(unknown), Murray Krahn, Fangyun Wu, Matthew B. Stanbrook, George Tomlinson, Kazuhiro Yasufuku, (unknown), Karen E. Bremner	1
2	A scoping review to create a framework for the steps in developing condition-specific preference-based instruments de novo or from an existing non-preference-based instrument: use of item response theory or Rasch analysis 2024 ·Health and Quality of Life Outcomes ·(unknown), (unknown), Joanna Bielecki, Nicholas Mitsakakis, Maureen Trudeau, Karen E. Bremner, Aileen M. Davis, Murray Krahn	0
3	INCREMENTAL HEALTH CARE UTILIZATION AND COST OF MALIGNANT PLEURAL EFFUSION 2024 ·CHEST Journal ·(unknown), Murray Krahn, (unknown), Matthew B. Stanbrook, George Tomlinson, Kazuhiro Yasufuku, (unknown), Karen E. Bremner	0
4	The impact of the early COVID-19 pandemic on healthcare system resource use and costs in two provinces in Canada: An interrupted time series analysis 2023 ·PLoS ONE ·(unknown), Douglas C. Cheung, Karen E. Bremner, Reka Pataky, Priscila Pequeno, John Matelski, Stuart Peacock, M. Elisabeth Del Giudice, Lauren Lapointe‐Shaw, George Tomlinson, (unknown), (unknown), (unknown), Nathan Perlis, Jennifer Walker, Beate Sander, William Wong, Murray Krahn, Girish S. Kulkarni	11
5	Cost-effectiveness analysis of genetic tools to predict treatment response in patients with cystic fibrosis 2023 ·Journal of Cystic Fibrosis ·Yeva Sahakyan, Lusine Abrahamyan, Félix Ratjen, Christine E. Bear, Lisa J. Strug, Paul D. W. Eckford, John K. Peel, Murray Krahn, Beate Sander	1
6	Economic evaluations and costing studies of lung transplantation: A scoping review 2021 ·The Journal of Heart and Lung Transplantation ·John K. Peel, Shaf Keshavjee, Murray Krahn, Beate Sander	11
7	Impact of direct‐acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta‐analysis 2021 ·Journal of Viral Hepatitis ·Yeva Sahakyan, (unknown), Karen E. Bremner, Joanna Bielecki, Murray Krahn	22
8	On the integration of early health technology assessment in the innovation process: reflections from five stakeholders 2020 ·International Journal of Technology Assessment in Health Care ·Marcia Tummers, Kari Jorunn Kværner, Laura Sampietro-Colom, (unknown), Murray Krahn, Øyvind Melien, Dominique Hamerlijnck, (unknown), Janneke P.C. Grutters	15
9	The emergency department as a setting‐specific opportunity for population‐based hepatitis C screening: An economic evaluation 2020 ·Liver International ·(unknown), David Naimark, William Wong, (unknown), Jordan J. Feld, Wanrudee Isaranuwatchai, Murray Krahn	19
10	Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada, using population‐based cohort studies 2020 ·Journal of Viral Hepatitis ·Abdullah Hamadeh, Alex Haines, Zeny Feng, Hla‐Hla Thein, Naveed Z. Janjua, Murray Krahn, William Wong	12
11	Long‐term morbidity and mortality in a Canadian post‐transfusion hepatitis C cohort: Over 15 years of follow‐up 2019 ·Journal of Viral Hepatitis ·Yeva Sahakyan, William Wong, Qilong Yi, Hla‐Hla Thein, George Tomlinson, Murray Krahn	4
12	Comparative Effectiveness of the Core Components of Cardiac Rehabilitation on Mortality and Morbidity: A Systematic Review and Network Meta-Analysis 2018 ·Journal of Clinical Medicine ·(unknown), George Tomlinson, Troy Francis, Sherry L. Grace, Gabriela Chaves, Valeria E. Rac, (unknown), Joanna Bielecki, David A. Alter, Murray Krahn	120
13	Using Phase-Based Costing of Real-World Data to Inform Decision–Analytic Models for Atrial Fibrillation 2016 ·Applied Health Economics and Health Policy ·(unknown), Walter P. Wodchis, Petros Pechlivanoglou, Jeffrey S. Hoch, Don Husereau, Murray Krahn	5
14	The reverse is true 2014 ·Canadian Medical Association Journal ·William B. Wong, Murray Krahn, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
15	Guidelines for Health Technologies: Specific Guidance for Oncology Products in Canada 2012 ·Value in Health ·Nicole Mittmann, William K. Evans, Angela Rocchi, Christopher J. Longo, Heather‐Jane Au, Don Husereau, Natasha B. Leighl, Pierre K. Isogai, Murray Krahn, Stuart Peacock, Deborah A. Marshall, Doug Coyle, (unknown), Philip Jacobs, Paul Oh	13
16	Impact of Androgen-Deprivation Therapy on Physical Function and Quality of Life in Men With Nonmetastatic Prostate Cancer 2010 ·Journal of Clinical Oncology ·Shabbir M.H. Alibhai, Henriette Breunis, Narhari Timilshina, (unknown), George Tomlinson, Ian F. Tannock, Murray Krahn, Neil Fleshner, Padraig Warde, S. Duff Canning, Lawrence Klotz, Gary Naglie	146
17	Impact of Androgen-Deprivation Therapy on Cognitive Function in Men With Nonmetastatic Prostate Cancer 2010 ·Journal of Clinical Oncology ·Shabbir M.H. Alibhai, Henriette Breunis, Narhari Timilshina, (unknown), (unknown), Ian F. Tannock, Gary Naglie, George Tomlinson, Neil Fleshner, Murray Krahn, Padraig Warde, S. Duff Canning	92
18	Feasibility of Internet-Based Health-Related Quality of Life Data Collection in a Large Patient Cohort 2010 ·Journal of Medical Internet Research ·(unknown), Noori Chowdhury, John Granton, Murray Krahn, D. Elizabeth Tullis, Thomas K. Waddell, L.G. Singer	19
19	Identifying the Best Treatment Among Common Nonsurgical Neck Pain Treatments 2008 ·Spine ·Gabrielle van der Velde, Sheilah Hogg‐Johnson, Ahmed M. Bayoumi, J. David Cassidy, Pierre Côté, Eleanor Boyle, Hilary A. Llewellyn‐Thomas, Stella Chan, (unknown), Jan L. Hoving, Eric L. Hurwitz, Claire Bombardier, Murray Krahn	22
20	Is there age bias in the treatment of localized prostate carcinoma? 2003 ·Cancer ·Shabbir M.H. Alibhai, Murray Krahn, Marsha M. Cohen, Neil Fleshner, George Tomlinson, Gary Naglie	86

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact